SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing extreme volatility as investors grapple with a combination of broader semiconductor sector weakness, geopolitical tensions in the Middle East, and persistent FUD surrounding memory demand. While many community members are aggressively buying the dip, citing strong long-term fundamentals and undervalued P/E ratios, others remain cautious, fearing further downside and potential supply chain disruptions from the ongoing conflict.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the stock's long-term potential in AI infrastructure against macro-driven sell-offs linked to geopolitical tensions and debt concerns. The community remains divided between those panic-selling and those adding to their positions, with sentiment heavily focused on the anticipation of new hyperscaler lease announcements serving as a major catalyst for a price recovery.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is experiencing significant volatility as investors closely monitor upcoming earnings and its strategic shift away from Chinese market dependencies. The community is actively debating the stock's long-term potential, heavily focused on government-backed price floors, defense sector partnerships, and the competitive race to build domestic magnet production infrastructure.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae shares are trending as high-profile investors like Bill Ackman and Michael Burry maintain bullish long-term stances, positioning the stock as a key political play tied to potential government release from conservatorship. While supporters view recent volatility as a strategic accumulation opportunity and highlight potential catalysts like Nasdaq tokenization or mortgage policy changes, others in the community remain skeptical due to the lack of clear timelines and the stock's dependence on political developments.

Maul Coin

Maul Coin is gaining significant traction as investors rally around its potential as a grassroots movement, with the community actively coordinating to sustain momentum and overcome whale sell pressure. Enthusiasts are drawing comparisons to other high-growth meme coins, focusing on collective holding strategies to increase market visibility and drive project adoption.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is seeing heightened volatility and intense trader interest as the market debates the sustainability of its rapid ascent, fueled by massive backlog growth and its strategic role in powering AI data centers. While some investors remain aggressively bullish on its 'bring-your-own-power' model and institutional partnerships, others are highlighting potential valuation concerns, insider selling, and the impact of sector-wide macro pressures.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant volatility as investors debate the potential for a foundry-led turnaround, further fueled by news of chip shortages and CPU price hikes across the sector. Community sentiment remains deeply polarized between those betting on long-term manufacturing recovery and those frustrated by persistent price pressure and geopolitical risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing significant volatility as investors weigh the company's shift toward high-performance AI data center infrastructure against concerns over share dilution and the lack of a major new contract announcement. While the community remains divided between long-term bulls highlighting massive energy capacity and GPU buildouts and frustrated traders reacting to daily price swings and macro-driven sell-offs, the stock continues to be heavily influenced by speculative deal rumors and institutional accumulation patterns.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest positive long-term data for sonelokimab in hidradenitis suppurativa, fueling debates over its "best-in-class" potential versus existing therapies. The community is actively discussing the stock's long-term clinical trajectory, ongoing buyout speculation involving major pharmaceutical players, and the impact of institutional accumulation amid persistent short-interest volatility.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors weigh the company's long-term growth driven by innovations in electrophysiology and the WATCHMAN FLX device against recent market volatility and analyst concerns regarding valuation premiums. The community is actively debating the stock's stability, with many highlighting the stock as a prime candidate for accumulation on dips while others express frustration over recent price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NextCure Shares Jump 15% After Private Placement Announcement

(RTTNews) - NextCure, Inc. (NXTC) rose 14.88% to $9.61, up $1.24, after announcing it has entered into a private placement of approximately $21.5 million, issuing 2,523,477 shares of common stock or...

Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NextCure, Inc. stock surged nearly 45% in Thursday's extended trading session after the biopharma firm unveiled new preclinical results showing its experimental antibody may offer a more effective treatment for osteogenesis imperfecta (OI), a rare genetic condition also known as brittle bone disease.In studies using a well-established mouse model of OI, NextCure stated that its NC605 candidate improved bone strength and quality, and reduced fracture rates, outperforming current experimental treatments, such as anti-sclerostin.Key findings from the study:<ul style="list-style-type:circle;"><li>NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.</li><li>Fracture incidence was lower in mice treated with a surrogate antibody compared to those receiving anti-sclerostin or placebo.</li><li>NC605 showed the potential to both prevent bone loss and promote new, stronger bone formation.</li></ul>"There is currently no standard of care approved by the FDA for patients with OI," said Dr. Priyanka Kothari, Director of Translational Research at NextCure. "NC605 has the potential to provide significant therapeutic benefit for patients."On Stocktwits, <a href="https://stocktwits.com/symbol/NXTC">NextCure</a> was among the top 10 trending tickers late Thursday, with sentiment turning 'extremely bullish' (94/100) and hitting its highest level this year, while message volume spiked.&nbsp;NXTC's retail following on the platform also rose by 2% following the news.Still, NextCure stock has shed over 43% of its value this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meme-stock-fever-hits-healthcare-triangle-stock/choGVbvR5vR">Meme Stock Fever Hits Healthcare: Nano-Cap HCTI More Than Doubles, Lifting Retail Mood To 2-Month High</a>

NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment

NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.

Equity

NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.


Shares of NextCure, Inc. (NXTC) slumped 27% on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/16/3099713/0/en/NextCure-and-Simcere-Zaiming-Announce-Strategic-Partnership-for-a-Novel-Antibody-Drug-Conjugate-Targeting-CDH6.html">announced</a> a strategic partnership with China-based Simcere Zaiming to develop a therapy for the treatment of solid tumors.Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Hong Kong-listed Simcere Pharmaceutical Group Ltd.The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. This compound has demonstrated robust anti-tumor activity across multiple solid tumor models in preclinical studies.Antibody-drug conjugates (ADCs) are a class of targeted cancer therapies designed to deliver chemotherapy directly to cancer cells, minimizing harm to healthy cells.The drug is currently in early-stage testing in China. NextCure anticipates commencing clinical testing in the United States in the third quarter of 2025, with early-stage clinical data anticipated in the first half of 2026.While NextCure will gain global rights to SIM0505, excluding Greater China, Simcere Zaiming will retain rights there, the company said.Simcere Zaiming is eligible to receive payments of up to $745 million throughout the potential development phases. This includes upfront payment, development, regulatory, and sales milestone payments.The China-based company is also eligible to receive tiered royalties up to double digits on net sales outside of the Greater China territory.On Stocktwits, retail sentiment around NextCure rose from ‘bullish’ to ‘extremely bullish’ territory over the past 12 months while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_12_05_23_PM_png_99a749c3d2.webp" alt="NXTC's Sentiment Meter and Message Volume as of 12:05 p.m. ET on June 16, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>NXTC's Sentiment Meter and Message Volume as of 12:05 p.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NXTC">NXTC stock</a> is down by about 39% this year and by about 65% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/abbvie-says-cancer-drug-failed-to-prolong-survival-in-late-stage-study/chlnHmLRRRA">AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline

The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. 

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in Phase 2 trials boasting market caps of over $500 million, Shuttle's valuation stands at just $4 million.<ul><li>Radiation therapy is a cornerstone of cancer treatment, with approximately 50% of cancer patients undergoing it during their illness. A sensitizer is a drug designed to enhance the effectiveness of radiation by making cancer cells more susceptible to damage while sparing healthy cells. This approach revolutionizes therapy by increasing tumor control and minimizing harmful side effects, particularly for aggressive cancers like glioblastoma. Shuttle Pharma’s Ropidoxuridine is at the forefront of this innovation. &nbsp;</li><li>Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. While several peer companies in Phase 2 trials boast market caps exceeding $500 million, Shuttle’s valuation stands at just $4 million. This mismatch reflects a significant opportunity for investors, as Shuttle is already enrolling patients in its Phase 2 trial for Ropidoxuridine. &nbsp;</li><li>Founded by Georgetown University faculty, Shuttle Pharma is led by experienced scientists and executives with decades of oncology expertise. The management team includes individuals responsible for bringing successful cancer therapies to market, further bolstering its credibility.</li></ul>&nbsp;Shuttle Pharmaceuticals: Revolutionizing Radiation Therapy by Making it More Effective at Killing Cancer Cells while Sparing Healthy Cells<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals/">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is a clinical-stage biotech company specializing in therapies that enhance the efficacy of radiation therapy while minimizing side effects. Beyond Ropidoxuridine, Shuttle Pharma’s pipeline includes promising candidates like SP-2-225 and SP-1-303, along with diagnostic tools that could streamline FDA approval and open additional revenue streams.Dr. Anatoly Dritschilo, the company’s CEO, brings decades of experience as a radiation oncology leader and professor at Georgetown University. His tenure at the institution has cemented his reputation as an innovator in radiosensitization and therapeutic resistance strategies.&nbsp;Hope for Those Facing a Ruthless CancerGlioblastoma (GBM) is one of the deadliest cancers, with a five-year survival rate of just 6.9% and an average survival of eight months. It impacts cognition, mood, and independence, placing emotional and financial burdens on patients and families. With only a handful of FDA-approved treatments, GBM remains a significant challenge, but innovations like Shuttle Pharma’s Ropidoxuridine offer hope for better outcomes.&nbsp;Pipeline Overview and Flagship DrugShuttle Pharma’s pipeline includes:<ul><li>Ropidoxuridine (IPdR): Their flagship radiation sensitizer in Phase 2 trials for glioblastoma. As a sensitizer, it enhances the vulnerability of cancer cells to radiation while sparing healthy tissues, leading to improved therapeutic outcomes. The drug has received an Orphan Drug Designation, ensuring market exclusivity upon approval (3). Early data supports its safety and oral bioavailability, with promising mechanisms to sensitize cancer cells without harming normal tissues.</li><li>SP-2-225: A preclinical HDAC6 inhibitor targeting immune activation post-RT. HDAC6 inhibitors are emerging as a transformative class of drugs with the potential to improve tumor recognition by the immune system (4). This drug could have broad applications combined with radiation therapy and other immune therapies, addressing a large oncology market.</li><li>SP-1-303: Another preclinical asset targeting estrogen receptor-positive breast cancers, a subtype that represents a significant portion of all breast cancer diagnoses. Its unique mechanism of action and potential synergy with current hormonal treatments create substantial commercial potential.</li></ul><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/shuttle_pharma_pipeline_8164d4c4cb.png" alt="shuttle-pharma-pipeline.png">&nbsp;Market Potential for Ropidoxuridine and Other CandidatesRadiation sensitizers represent a multi-billion-dollar opportunity. The global radiation therapy market is projected to grow significantly, reaching $14.18 billion by 2028 (2). Approximately 50% of all cancer patients undergo radiation therapy, amounting to a substantial number of patients annually in the US alone (1). A significant portion of these patients are treated with curative intent, offering a target market potentially worth billions for sensitizing agents.With glioblastoma as the initial target, Shuttle’s technology could eventually expand into other cancer types where radiation is a core treatment modality, such as lung, breast, and gastrointestinal cancers. By reducing radiation toxicity and improving tumor control, Ropidoxuridine could become an essential adjunct to standard cancer care.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/global_radiation_therapy_market_graph_9d83a88dbe.jpeg" alt="global-radiation-therapy-market-graph.jpeg">Simple Mechanism of Action and Proven SafetyRopidoxuridine acts as a prodrug, metabolized into IUdR upon ingestion. IUdR incorporates into cancer DNA, enhancing RT-induced DNA damage while sparing healthy cells.In layman’s terms, Ropidoxuridine is like a “homing beacon” for radiation therapy, guiding the radiation to attack cancer cells while avoiding healthy tissues. This straightforward and targeted approach significantly increases the likelihood of clinical success compared to more complex therapies.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/how_does_ropidoxuridine_work_17eaa74e99.png" alt="how-does-ropidoxuridine-work.png">Comparative Analysis: Valuation vs. PeersBiotech valuations often evolve significantly as companies progress through clinical trials. For Phase 1 assets, the average valuation tends to hover between $100 – $250 million, while Phase 2 assets range from $250 – $750 million (5). Currently valued at approximately $4 million, Shuttle Pharma is an outlier, suggesting it should be 25x higher based on similar Phase 2 comparables. If Ropidoxuridine demonstrates efficacy, the company could see valuations 100x higher, reflecting the upside potential.&nbsp;Similar Stage Comparisons: Phase 2 Enrollment<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/leap-therapeutics">Leap Therapeutics (NASDAQ: LPTX)</a><ul><li>Market Cap: Approximately $82 million</li><li>Focus: Antibody-based therapies targeting immune modulation in cancer.</li><li>Pipeline: DKN-01, currently in Phase 2 for gastric and gynecologic cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">(4)</a>.</li><li>Comparison Insight: Leap Therapeutics commands a valuation over 20x that of Shuttle Pharma, underscoring the latter’s deep undervaluation relative to its stage of development.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/nextcure">NextCure (NASDAQ: NXTC)</a><ul><li>Market Cap: Approximately $23 million</li><li>Focus: Immune therapies targeting novel tumor-specific antigens.</li><li>Pipeline: NC318, currently in Phase 2 trials for advanced solid tumors.</li><li>Comparison Insight: NextCure reflects the market’s optimism for immune-oncology therapies in Phase 2 trials.</li><li>Demonstrated Efficacy Comparisons: Post-Positive Phase 2</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/kura-oncology">Kura Oncology (NASDAQ: KURA)</a><ul><li>Market Cap: Approximately $620 million</li><li>Focus: Precision oncology for genetically defined cancers.</li><li>Pipeline: Tipifarnib, demonstrating efficacy in Phase 2 for HRAS-mutant cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">(6)</a>.</li><li>Comparison Insight: Kura highlights the potential valuation growth when efficacy is shown in Phase 2 for a targeted therapeutic.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/adicet-bio">Adicet Bio (NASDAQ: ACET)</a><ul><li>Market Cap: Approximately $76 million</li><li>Focus: Allogeneic gamma-delta T cell therapies for oncology.</li><li>Pipeline: ADI-001, demonstrating Phase 2 efficacy in B-cell lymphomas.</li><li>Comparison Insight: Adicet underscores how valuation grows post-efficacy, aligning with Shuttle Pharma’s potential trajectory.</li></ul>&nbsp;An Accomplished Team Backed by Prestigious InstitutionsShuttle Pharma’s leadership is grounded in expertise, with key team members boasting extensive experience in oncology drug development:<ul><li>Dr. Anatoly Dritschilo: CEO and co-founder, a globally recognized radiation oncology expert with over 40 years of experience. Dr. Dritschilo has published extensively on radiation therapy and drug discovery and is an innovator in developing strategies for radiosensitization and therapeutic resistance.</li><li>Dr. Tyvin Rich: Medical Director with experience at MD Anderson and Harvard, specializing in radiation sensitizers.</li><li>Dr. Mira Jung: Scientific Director and co-founder, a professor of Radiation Medicine at Georgetown University.</li></ul>The rest of the team comprises an impressive roster of PhDs, MDs, and industry veterans with decades of combined experience developing oncology therapies and navigating FDA regulatory pathways.Strong Insider Ownership and Shareholder AlignmentWith 28.3% insider ownership, including a significant investment from the CEO, Shuttle Pharma’s management is deeply aligned with shareholder interests. This rare level of insider ownership reflects confidence in the company’s potential. High insider ownership ensures that decision-makers have “skin in the game,” aligning their financial interests with investors and creating trust in long-term value creation. Additionally, if clinical data supports efficacy, the small public float (2.9 million shares) positions the stock for dramatic price appreciation.Conclusion: The Undervalued Biotech to WatchShuttle Pharma’s small float, strong leadership, and groundbreaking focus on radiation sensitizers position it as one of the most undervalued opportunities in biotech. With a Phase 2 trial underway and a massive addressable market, Shuttle could redefine cancer treatment while offering exponential upside for investors. Comparisons to higher-valued peers only underscore the gap—and the potential for rapid revaluation if results prove successful.Shuttle Pharma’s other drug candidates, including SP-2-225 and SP-1-303, offer compelling bonuses for investors. These unique yet complementary assets could potentially expand Shuttle’s market reach in oncology. Additionally, the company’s diagnostic tools present a unique opportunity: they often have more streamlined FDA approval processes than therapeutics and could potentially be spun off as a standalone business, unlocking significant shareholder value.References<ol><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cancer.org/cancer/managing-cancer/treatment-types/radiation/basics.html">American Cancer Society: Radiation Therapy Overview</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.researchandmarkets.com/report/radiation-therapy?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kpswcb&amp;utm_campaign=1977747+-+Global+Radiation+Therapy+Market+with+Focus+on+LINAC%2c+2024+Market+Report%3a+A+%2414.18+Billion+Market+in+2028%2c+Registering+a+Projected+CAGR+of+6.75%25+During+2024-2028&amp;utm_exec=carimspi">Global Radiation Therapy Market Report</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=519016">FDA Orphan Drug Designation List</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">Leap Therapeutics Corporate Pipeline</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8854317/">Biotech Valuation Trends</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">Kura Oncology: Pipeline</a></li></ol>This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Nextcure Inc

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

NXTC
Nextcure Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NXTC News

NXTCNextcure Inc